Nina Kjellson has been part of InterWest's life sciences team since 2002, focusing primarily on investments in biopharmaceuticals. She is a board member of Alvine Pharmaceuticals, Cebix, CNS Therapeutics, Eiger Biopharmaceuticals, Lycera, PrimeraDx and Trius Therapeutics. Kjellson led InterWest's investment in APT Pharmaceuticals where she is an observer on the board and is also involved in InterWest's investment in TESARO.

Prior to joining InterWest, Kjellson was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a healthcare-focused hedge fund. Kjellson began her career conducting health policy and survey research with the Kaiser Family Foundation.

Kjellson received a B.A. in human biology from Stanford University. She also serves on the Advisory Board of The Consumer Med Summit.

Previous Representative Investments

Aspreva Pharmaceuticals, acquired by Galenica
NovaCardia, acquired by Merck (MRK)

A Word from Nina

"I've always known that my career would focus on medicine and the life sciences as I am committed to advancing healthcare technologies and improving access to care. At InterWest, I aim to implement an investment strategy that integrates market vision and technical innovation with sound business planning and leadership. In so doing, it is my objective to partner with the entrepreneurs and scientists working to change the face of healthcare."

Email Nina»